Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status

These results strongly argue against generalizing the observations made in mesothelioma to all cancer syndromes with BAP1 deficiencies.

Abstact

Our data on UM are in marked contrast to the reported role of EZH2 in mesothelioma. Our results strongly argue against generalizing the observations made in mesothelioma to all cancer syndromes with BAP1 deficiencies. We suggest that careful examination of the response to EZH2 inhibitors in each specific cancer type should be done before proposing the use of these molecules for therapeutic approaches.

To download this paper, please click here.

Related